Factor 8 Hemlibra denied for failing step therapy by Aetna?

Aetna's specific coverage criteria for factor 8 hemlibra are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Aetna Applies Step Therapy to Hemlibra — and Why You Can Appeal

Hemlibra (emicizumab-kxwh) is FDA-approved for hemophilia A prophylaxis. Aetna's step-therapy requirements for Hemlibra typically specify that the patient must have documented inhibitor development, a history of prior factor VIII prophylaxis, or other clinical prerequisites before Hemlibra is approved as a first-line agent — particularly for patients without inhibitors, where the treatment algorithm is more nuanced. A step-therapy denial means the plan's reviewer determined that the required prior steps were not documented, not that Hemlibra is clinically inappropriate.

## Why This Denial Is Appealable

Step-therapy requirements must be clinically reasonable and applied based on Aetna's published written criteria. If the required prior steps have in fact been completed and the documentation was not submitted, an appeal with corrected documentation frequently succeeds at the internal stage. If the step-therapy requirement is clinically inappropriate for this specific patient — because the required prior therapy is contraindicated, was tried and failed, or cannot be used safely — most states and ERISA regulations require the plan to grant an exception. Many states have enacted explicit step-therapy reform laws mandating exception pathways.

## Federal Appeal Framework

• ERISA §503 (self-funded plans): Full-and-fair review; file within 180 days of the denial notice.
• ACA §2719 (fully-insured plans): Independent external review after internal exhaustion; typically within four months of the final internal denial.
• Expedited review: If requiring the step-therapy agent would place the patient at imminent bleed risk, request expedited processing — typically 72-hour resolution at both the internal and external stages.

## Concrete Appeal Steps and Timeline

1. Obtain the denial notice and identify precisely which step-therapy prerequisites Aetna says are unmet. 2. Request Aetna's full written coverage policy for Hemlibra, including step-therapy criteria. 3. Audit the clinical record against each prerequisite. 4. If prerequisites were met, gather the documentation that demonstrates this. 5. If prerequisites cannot be met safely, document the clinical reason. 6. File the internal appeal with a structured criteria-mapping letter. 7. If denied internally, escalate to external review within four months.

## Documentation to Gather

• Inhibitor status: Laboratory documentation of factor VIII inhibitor presence or absence, with dates.
• Prior-treatment history: Every prior prophylaxis or on-demand factor therapy — product name, dates, dosing regimen, duration, and outcome — particularly any product specified in Aetna's step-therapy policy.
• Failure or inadequacy evidence: Breakthrough bleeding events, annualized bleed rate on prior therapy, inhibitor development records, or documented intolerance.
• Diagnosis confirmation: Specialist-confirmed hemophilia A diagnosis from a hematologist or comprehensive hemophilia treatment center.
• Prescriber medical-necessity letter: The treating hematologist should address each step-therapy criterion in Aetna's policy, explain why each required step was completed or why it cannot be completed for this patient, and reference the applicable clinical guideline organization (e.g., ASH or WFH) without asserting specific numeric thresholds.

## Criteria-Mapping Structure

Print Aetna's step-therapy requirements verbatim in a table. For each requirement, provide the chart document, date, and exact finding that satisfies it — or, for any requirement the patient cannot safely complete, a clinical explanation signed by the treating hematologist. Where applicable, cite your state's step-therapy reform statute by name and note that it requires Aetna to grant an exception in these circumstances. This combination of medical evidence and legal basis is the most effective structure for step-therapy appeals in hemophilia A.